A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering.

摘要: It has become evident that cardiovascular disease is the major cause of morbidity and mortality in type 2 diabetes mellitus. This raises possibility glucose lowering agents with other nonglucose-lowering effects, might have added benefits. In this review, we focus on metabolic effects oral antidiabetic go beyond glucose-level lowering. Such include lipid modifying actions, antithrombotic profibrinolytic activities, direct action at level vessel wall to improve endothelial function or prevent smooth muscle hyperplasia. These additional particularly those seen newer agents, hold promise reducing complications achievable by alone.